Endotoxin (lipopolysaccharide, LPS) and interleukin-1 (IL-1) reduce food intake in rodents. Cyclooxygenase (COX) inhibitors have long been known to attenuate these responses, but recent work has revealed the existence of two distinct isoforms of the enzyme, COX1 and COX2, with different characteristics and functions. Therefore, we reassessed the COX involvement using inhibitors with different selectivities for COX1 and COX2. Feeding was assessed in nondeprived mice by measuring the intake of sweetened milk in a 30-minute period, as well as daily food pellet intake. LPS and IL-1β consistently reduced milk intake. Treatment of the mice with the selective COX1 inhibitor, piroxicam, attenuated the hypophagic responses to IL-1 and LPS. Similar results were obtained with diclofenac. The hypophagic responses to LPS and IL-1β were not affected by the COX2-selective inhibitors nimesulide and NS-398 at doses considered selective for COX2, but were inhibited by higher doses. Pretreatment of the mice with aspirin, an irreversible inhibitor of COX1 and COX2, prevented the hypophagic response to IL-1, 16 h, but not 40 h later. Taken together, these results suggest that COX1 may be the major isozyme involved in the hypophagic responses to LPS and IL-1, but a role for COX2 cannot be excluded. We also studied the combination of a COX inhibitor with the IL-1 receptor antagonist protein. Consistent with earlier results, both the IL-1 receptor antagonist (IL-1ra) and indomethacin attenuated the hypophagic responses to LPS. Combination of the two treatments produced additive results almost completely preventing the hypophagic response. Because indomethacin almost completely prevented the hypophagic response to IL-1, this additivity suggests that there are multiple mechanisms by which LPS induces hypophagia.
Administration of bacterial endotoxin (lipopolysaccharide, LPS) or interleukin-1 (IL-1) inhibits food intake in rats (Langhans, Savoldelli, & Weingarten, 1993) and mice (Swiergiel, Smagin, & Dunn, 1997a) . Inhibitors of cyclooxygenase (COX), the key enzyme initiating the synthesis pathways for prostaglandins, prostacyclins, and thromboxanes, have been shown to attenuate these hypophagic responses (Hellerstein, Meydani, Meydani, Wu, & Dinarello, 1989; Langhans et al., 1993; Swiergiel et al., 1997a) . COX inhibitors generally have a greater effect on the responses to IL-1 than to LPS (Swiergiel et al., 1997a) . The location of the COX enzymes involved in this response has not been established, but speculation centers around the COX expressed in endothelial cells of the cerebral capillaries (Breder, 1997; Cao, Matsumura, Yamagata, & Watanabe, 1996) . Recent evidence has indicated the existence of two different COX isozymes, COX1 and COX2 (Frölich, 1997) . COX1 is constitutively expressed in many tissues, whereas COX2 is inducible and may play an impor-
